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The in vivo regional distribution of [‘*F]GBR 13119 (l-[(4-[‘8F]fluorophenyl(phenyl)methoxy)ethyl]-4-(3- 
phenylpropyl)piperazine), a specific dopamine reuptake inhibitor, was examined in brains of C57BL/6 
mice after MPTP treatment. At 2 weeks post MPTP the in vivo specific binding of [‘*F]GBR 13119 in 
striatum was decreased 63% relative to age and sex-matched controls. Animals studied at 6 and 8 weeks 
after MPTP treatment showed a eradual recoverv of soecific I’sFIGBR 13119 bindine in the striatum. No 
significant changes were observed-in binding of radiotracer to’cerebellum or cortex after MPTP treatment, 
nor were age-related changes observed in control mice. In vivo radiotracer studies thus appear useful for 
following gradual changes in the dopamine uptake system of mouse brain after neurotoxin treatment. 
Introduction 
Although the MPTP (I-methyl-4-phenyl- 1,2,3,6- 
tetrahydropyridine)-treated mouse has seen extensive 
use as a model of Parkinson’s disease (review: Kopin 
and Markey, 1988), it differs from idiopathic parkin- 
sonism in that the onset of neuronal degeneration is 
very rapid and is followed by slow recovery of the 
dopaminergic system. The return of endogenous 
dopamine levels to higher levels is now well docu- 
mented (Kopin and Markey, 1988; Ricuarte er af., 
1987). Similar changes in the neuronal dopamine 
reuptake system, which is responsible for termination 
of neurotransmission by removal of dopamine from 
the synapse, have been reported using in vitro 
methods. After MPTP treatment there is a rapid 
decline in DA uptake (V,,,, using [3H]dopamine: 
Jossan et al., 1989; Ricuarte et al., 1987), and de- 
creased binding of [‘Hlmazindol to the DA trans- 
porter site in striatal synaptosomal preparations 
(Ricuarte er af., 1987; Sershen et al., 1985; Sundstrum 
et al., 1988) or striatal tissue by in vitro autoradio- 
graphy (Donnan et al., 1987). The dopamine re- 
uptake system also appears to recover with time, and 
the number of DA uptake sites as determined by in 
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vitro [3H]mazindol binding appears to correlate with 
endogenous DA levels (Donnan et al., 1987). 
We have developed the new radioligands [“F]GBR 
12909 ( I-[(4-[‘sF]fluorophenyl(4-fluorophenyl)- 
methoxy)ethyl]-4-(3-phenylpropyl)piperazine; Maka 
and Kilbourn, 1990) and [‘*F]GBR 13119 
(( l-[(4-[‘BF]-fluorophenyl(phenyl)methoxy)ethyJ]-4- 
(3-phenylpropyl)piperazine: Kilbourn and Haka, 
1988; Haka et al., 1989) for the in vivo study of the 
DA uptake system, and have recently reported the 
regional in uivo binding and pharmacological specifi- 
city of these radioligands in mouse, rat, monkey and 
human brain (Kilbourn, 1988; Kilbourn et al., 1989a, 
b; Ciliax er al., 1990; Koeppe et al., 1990). Although 
the MPTP rodent has been extensively studied using 
in vitro techniques, very few in vivo experiments have 
been reported, mostly due to the lack of suitable 
radioligands. A thorough understanding of the extent 
and time course of recovery of the dopaminergic 
system in MPTP-treated rodents will be important in 
the interpretation of results of studies into new 
preventative or therapeutic strategies for neurodegen- 
erative diseases such as Parkinson’s disease. The 
availability of new radioligands such as [‘“FIGBR 
13119 and [18F]GBR 12909, which can be synthesized 
in high specific activity (>2000 Ci/mmol), makes 
possible in uivo studies of the DA reuptake system in 
the MPTP mouse model. We report here that 
[18F]GBR 13119 can be used to demonstrate in viuo 
loss of DA reuptake sites after MPTP treatment, and 
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furthermore that this in uivo radiotracer technique 
has the sensitivity to show the gradual recovery of 
this nemotransmitter reuptake system. 
Discussion 
Materials and Methods 
[“F]GBR 13119 (specific activity > 2000 Ci/mmol) 
was prepared according to literature methods (Kil- 
bourn and Haka, 1988; Haka et al., 1989). MPTP 
was prepared by the methylation of 4-hydroxy-4- 
phenylpiperidine (Aldrich Chem. Co.) followed by 
acid-catalyzed dehydration. Mice (C57BL/6, male, 
25-30 g, 13-l 5 weeks: Charles River) were injected 
four times with 10 mg/kg i.p. MPTP at 1 h intervals 
(Ricuarte et al., 1987). Animals were then used for 
brain biodistribution studies at 2, 6 and 8 weeks 
following MPTP treatment; at each time point an 
equal number of control animals, age- and sex- 
matched, were also studied. Mice (controls or MPTP- 
lesioned) were injected via the tail vein with 3-10 PCi 
of [‘*F]GBR 13119 (< 1 ng/kg, in isotonic saline). At 
60 min the animals were killed by decapitation, and 
the brain rapidly removed and dissected into regions 
of interest (striatum, cortex, cerebellum, rest of brain) 
and a blood sample obtained. The tissue samples 
were then weighed and counted for fluorine-18. Data 
were calculated as % injected dose/g (% I.D./g) for 
all tissues, and analyzed for significance using an 
unpaired Student’s t-test. 
[‘*F]GBR 13119 is a high affinity radioligand for 
the dopamine uptake site which shows good pharma- 
cological selectivity in viuo (Kilbourn, 1988; Kilbourn 
ef al., 1989a, b; Ciliax et al., 1990). The specific 
binding of this radioligand to sites in the striatum of 
mice is significantly decreased (63%) at 2 weeks after 
systemic MPTP treatment (Table 1). This is similar to 
in vitro decreases of 40-80% in [3H]mazindol binding 
to striatal tissue (Ricuarte et al., 1986; Sershen et al., 
1985; Sundstrom et al., 1988) and losses of dopamine 
of as much as 80% (Nishi et al., 1989; Ricuarte et al., 
1987; Sundstrom et al., 1988). No significant changes 
were observed in [‘*F]GBR 13 119 binding in cortex or 
cerebellum. Cerebellar radioactivity levels should rep- 
resent mostly non-specific binding, as no dopamine 
uptake sites have been observed in the cerebellum 
using in vitro autoradiography ([‘Hlmazindol: Don- 
nan et al., 1989) or photoaffinity labeling experiments 
(Grigoriadis et al., 1989). We have consistently ob- 
served slightly higher cortical [‘*F]GBR 13119 levels 
(cortex/cerebellum values of 1.1-I .3), but this binding 
(if to DA uptake sites) may not be affected by MPTP 
treatment. 
Results 
The time course study of [‘*F]GBR 13119 binding 
(Table 1) shows a gradual recovery of the striatal DA 
uptake system over the 8 week period: full recovery 
has not been achieved, as STR/CER ratios remain 
depressed at the end of the study. This is consistent 
with the demonstration of recovery of dopamine 
uptake sites in vitro using [jH]mazindol binding to 
mouse brain striatal membranes (Donnan et al., 
1987), where control values were reached after 1 year. 
At 2 weeks after MPTP treatment there is a [‘*F]GBR 13119 would thus appear a suitable 
significant loss of in vivo [‘*F]GBR 13119 binding to marker for dopaminergic terminals in the striatum of 
mouse striatum (Table 1). The data are presented mice, and the loss and subsequent recovery of DA 
both as regional brain distributions (% I.D./g) and uptake sites after MPTP treatment have for the first 
target to non-target ratios (% I.D. striatum/% I.D. time been demonstrated using in uivo radiotracer 
cerebellum; STR/CER). The STR/CER ratios were techniques. The recovery of DA reuptake sites with 
statistically identical between all control groups time is consistent with the proposals of regrowth of 
demonstrating no age-related dependence of the dopaminergic terminals from areas which are less 
dopamine uptake system during the time period sensitive to the toxin (ventral tegmental area, sub- 
(13-24 weeks) studied here; this is consistent with the stantia nigra) (Donnan et al., 1987; Kopin and 
literature (Jonec and Finch, 1975; Strong et al., 1984) Markey, 1988). The availability of such high specific 
and therefore all control animals were combined into activity, specific radioligands for in viuo studies elim- 
a single group. The loss of specific [‘*F]GBR 13 119 inates possible problems with using less specific radio- 
binding in the striatum [defined here as % I.D. STR ligands such as [3H]mazindol or [3H]nomifensine, 
minus % I.D. CER, where cerebellum is assumed to be which bind to both dopamine and norepinephrine 
completely void of dopaminergic terminals (Grigori- reuptake sites. The use of [“F]GBR 13119 may also 
adis et al., 198911 at 2 weeks is approx. 63% (controls, avoid difficulties with the use of [3H]GBR 12935 and 
1.02 + 0.12; MPTP-treated, 0.382 + 0.22, P < 0.006). in vitro analysis methods, in which a second binding 
Table I. Time course of changes in regional brain distribution of [‘*F]GBR 13119 in control and 
MPTP-lesioned CS7BL/6 mice. Values shown are mean + SD 
% Injected dose/g 
Striatum Cerebellum Cortex Striatum/cerebellum 
Control 1.47_+0.13 0.45 + 0.04 0.76 _+ 0.06 3.1 + O.l6(n = 16) 
2 weeks post MPTP 0.86 f 0.17** 0.48 If: 0.1 I 0.64 f 0.14 1.87 f 0.3’ (n = 4) 
6 weeks post MPTP I .25 + 0.07 0.48 f 0.12 0.66 _+ 0.02 2.3 f 0.20** (a = 4) 
8 weeks post MPTP 1.28 f 0.31 0.47 f 0.06 0.66 f 0.05 2.7 + 0.14” (a = 7) 
*P < 0.01; **P < 0.05; Student’s r-test 
[‘*F]GBR 13119 in MPTP mice 805 
site for this class of compounds has been described: Haka M. S., Kilboum M. R., Watkins G. L. and Tooron- 
originally termed a “piperazine acceptor site” gian S. A. (1989) Aryltrimethylammonium trifluoro- 
(Andersen, 1987, 1989; Andersen et al., 1987) it has 
methanesulfonates as precursors to aryl [‘*F]fluorides: 
been more recently identified as the cytochrome 
improved synthesis of [“FJGBR 13119. J. Labelled 
Compd. Radiopharm. 21, 823-833. 
P450IIDl enzyme present in brain tissue (Niznik Jonec V. and Finch C. E. (1975) Ageing and dopamine 
et al., 1990). Importance of this second binding site uptake by subcellular fractions of the C57BL/6 male 
to our in ~iuo results obtained with [“F]GBR 13119 
mouse brain. Brain Res. 91, 197-215. 
remains unclear (Kilbourn et al., 1989b), although it 
Jossan S. S., Sakurai E. and Oreland L. (1989) MPTP 
toxicity in relation to age, dopamine uptake and MAO-B 
probably contributes to overall radioligand binding activity in two rodent species. Pharmacol. Toxicol. 64, 
in the brain, and has been recently proposed as the 314-318. 
explanation for the mismatch between losses of DA Kilboum M. R. (1988) in viuo binding of [‘*F]GBR 13119 
uptake sites measured with this type of radioligand 
to the brain dopamine uptake system. L[fi Sci. 42, 
1347-1353. 
(40-60% including Present work) and the much Kilbourn M. R. and Haka M. s. (1988) Synthesis of 
greater losses of endogenous dopamine (> 95%) (See- [18F]GBR 13119, a presynaptic dopamine uptake antag- 
man and Niznik, 1990). 
important neuronal system (Zigmond and Stricker, 
The study of the time course of [18F]GBR 13119 
binding in recovering MPTP-treated mice also 
1989), whether the degeneration is of natural cause 
demonstrates that such in viva radiotracer techniques 
may have the sensitivity needed to measure gradual 
(Parkinson’s disease) or neurotoxin produced 
changes in the dopaminergic system, presumably 
(MPTP, methamphetamine; Wagner et al., 1980). 
representing changes in the number of dopaminergic 
terminals. In this study, specific binding was esti- 
mated using simple target to non-target ratios: appli- 
cation to human studies using PET may require more 
complex pharmacokinetic modeling approaches 
(Koeppe et al.. 1990). Such studies may be of con- 
siderable value in the study of new pharmacological 
approaches to prevent or treat degeneration of this 
onist. Appl. Radiat. Isot. 39, 279-282. 
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